A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
Public ClinicalTrials.gov record NCT05559476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-label, Randomized, Controlled, Multicountry Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU HD Vaccine in Adults Aged 65 Years and Above
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
Study identification
- NCT ID
- NCT05559476
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,029 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2022 (Actual)
- Primary completion
- Mar 7, 2023 (Actual)
- Completion
- Aug 15, 2023 (Actual)
- Last update posted
- Sep 24, 2024
2022 – 2023
United States locations
- U.S. sites
- 46
- U.S. states
- 23
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35205 | — |
| GSK Investigational Site | Tempe | Arizona | 85281 | — |
| GSK Investigational Site | Canoga Park | California | 91303 | — |
| GSK Investigational Site | Colton | California | 92324 | — |
| GSK Investigational Site | Sacramento | California | 95864 | — |
| GSK Investigational Site | San Diego | California | 92103-6204 | — |
| GSK Investigational Site | Walnut Creek | California | 94598 | — |
| GSK Investigational Site | Aurora | Colorado | 80012 | — |
| GSK Investigational Site | Coral Gables | Florida | 33134 | — |
| GSK Investigational Site | Fort Myers | Florida | 33912 | — |
| GSK Investigational Site | Hialeah | Florida | 33012 | — |
| GSK Investigational Site | Immokalee | Florida | 34142 | — |
| GSK Investigational Site | Miami | Florida | 33016 | — |
| GSK Investigational Site | Miami | Florida | 33184 | — |
| GSK Investigational Site | Orlando | Florida | 32801 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33409 | — |
| GSK Investigational Site | Sandy Springs | Georgia | 30328 | — |
| GSK Investigational Site | Savannah | Georgia | 31406 | — |
| GSK Investigational Site | Chicago | Illinois | 60640 | — |
| GSK Investigational Site | Evansville | Indiana | 47714 | — |
| GSK Investigational Site | Mishawaka | Indiana | 46544 | — |
| GSK Investigational Site | Valparaiso | Indiana | 46383 | — |
| GSK Investigational Site | Ames | Iowa | 50010 | — |
| GSK Investigational Site | El Dorado | Kansas | 67042 | — |
| GSK Investigational Site | Methuen | Massachusetts | 01844 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55402 | — |
| GSK Investigational Site | St Louis | Missouri | 63141 | — |
| GSK Investigational Site | Grand Island | Nebraska | 68803 | — |
| GSK Investigational Site | Papillion | Nebraska | 68046 | — |
| GSK Investigational Site | North Las Vegas | Nevada | 89030 | — |
| GSK Investigational Site | Warren Township | New Jersey | 07059 | — |
| GSK Investigational Site | Hickory | North Carolina | 28601 | — |
| GSK Investigational Site | Rocky Mount | North Carolina | 27804 | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45236 | — |
| GSK Investigational Site | Edmond | Oklahoma | 73013 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15243 | — |
| GSK Investigational Site | Columbia | South Carolina | 21045 | — |
| GSK Investigational Site | North Charleston | South Carolina | 29405 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | Jefferson City | Tennessee | 37760 | — |
| GSK Investigational Site | Memphis | Tennessee | 38119 | — |
| GSK Investigational Site | Nashville | Tennessee | 37912 | — |
| GSK Investigational Site | Austin | Texas | 78745 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | San Antonio | Texas | 78237 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05559476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 24, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05559476 live on ClinicalTrials.gov.